Novo Nordisk’s Ozempic reduces risk of kidney disease progression: study (NYSE:NVO)
Novo Nordisk’s (NVO) blockbuster diabetes drug, Ozempic (semaglutide), reduced the risk of kidney disease progression in a late-stage trial, the company announced on Tuesday.
Initiated in 2019, FLOW was a placebo-controlled, superiority trial comparing injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care on kidney outcomes for prevention of progression of kidney impairment and risk of kidney and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease.
Semaglutide 1.0 mg demonstrated 24% reduction in the risk of kidney disease-related events in the trial population, thus achieving the study’s primary endpoint. The drug also appeared to have a safe and well-tolerated profile in line with previous semaglutide 1.0 mg trials.
The announcement today follows the decision to stop the trial early due to efficacy, which was announced on October 10, 2023, based on a recommendation from an independent data monitoring committee.
The Danish drugmaker plans to file for regulatory approvals of a label expansion for Ozempic in the U.S. and EU in 2024.
Shares of Novo Nordisk (NVO) were down 1.83% premarket
